Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SXTP with free AI briefings, catalyst countdowns, and dilution alerts.

SXTP · 60 Degrees Pharmaceuticals, Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1M Cash on Hand
1.2mo Cash Runway
Follow SXTP by email Get an email when SXTP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SXTP, unsubscribe in one click. Privacy

📣 What SXTP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Celgosivir Dengue Fever Phase 1/2 · NCT02569827 Withdrawn
Modipafant Dengue Fever Phase 1/2 · NCT02569827 Withdrawn
Tafenoquine Babesiosis Phase 2 · NCT06207370 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SXTP holds $1M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 1.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SXTP files for a raise →

👥 Who Owns SXTP

Insiders 17.2% Other 5%+ holders 13.7% Institutions (11 holders) 20.7% Public and other holders 48.4%
HolderTypeShares% of sharesAs of
Knight Therapeutics Inc.
10% owner
Insider 658,629 14.69% 2026-07-22
Mitchell P. Kopin Institution (13G, 5%+) 390,342 8.70% 2026-09-30
Orca Capital AG 5%+ holder (13G) 222,934 4.97% 2026-11-05
CVI Investments, Inc. 5%+ holder (13G) 197,911 4.41% 2026-03-31
Lind Global Fund III LP 5%+ holder (13G) 191,571 4.27% 2026-07-31
Tyrone Miller
CFO · +75,000 options
Insider 26,370 0.59% 2025-01-17
Geoffrey S Dow
President and CEO, Director · +550,974 options
Insider 24,131 0.54% 2026-06-12
Cheryl Xu
Director · +200,000 options
Insider 15,816 0.35% 2025-06-03
Paul Field
Director · +4,000 options
Insider 14,000 0.31% 2023-12-31
Stephen Toovey
Director · +4,000 options
Insider 14,000 0.31% 2023-12-31
Charles W Allen
Director · +4,000 options
Insider 14,000 0.31% 2023-12-31
Kristen Landon
Chief Operating Officer · +4,167 options
Insider 4,540 0.10% 2025-01-17

Share count 4,484,622 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SXTP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SXTP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.